|Professor Clive Roy Taylor, MA, MD(Cantab), DPhil (Oxon)
Department of Pathology, Keck School of Medicine, University of Southern California, Los Angeles
|Professor Taylor holds M.A. and M.D. degrees from the University of Cambridge, and M.A. and D. Phil degrees from the University of Oxford. Dr. Taylor was appointed Lecturer at the University of Oxford, in 1970. A "Traveling Fellowship" in Cancer Research took Dr. Taylor to the University of Southern California in 1975, where he subsequently was appointed to the Chair of the Department of Pathology in 1984, a position that he held for 25 years. He also served as Senior Associate Dean for Educational Affairs at the Keck School of Medicine, from 1998 to 2009. Professor Taylor is a Fellow of the Royal College of Pathologists (U.K.), a Diplomate of the American Board of Pathology, a Member of the Royal College of Physicians (Ireland), and a Member of the Royal Society of Medicine. Professor Taylor chaired an FDA Advisory Panel for Diagnostic Devices and Radiology until 2007. His primary research relates to advanced methods of diagnosis and treatment of cancer, by immunologic and molecular methods. He has published more than 400 scientific papers and 12 books. He is Editor-in-Chief of Applied Immunohistochemistry and Molecular Morphology, and is a Trustee and Past President of the US. Biological Stain Commission. Dr. Taylor is married with four children, all of whom are physicians.|
|Mogens Vyberg, MD
Senior consultant, Professor of clinical pathology and Director of NordiQC
Vice President, President Elect
|Mogens Vyberg graduated with MD in medicine 1973 and was board-certified as specialist in pathology 1984. Since 1988, he has been senior consultant at the Institute of Pathology, Aalborg Hospital, and was appointed as professor of clinical pathology at Aalborg University Hospital in 2012.
Mogens Vyberg’s main clinical expertise and research fields are gastrointestinal, liver and brain pathology, immunohistochemistry and image analysis. He is author and co-author of about 130 scientific papers and several book chapters in these fields. He is head of the Laboratory for immunohistochemistry/R&D, which carries out quality control and protocol optimization for the world’s leading diagnostics companies.
He is also co-founder and director of the international organization Nordic Immunohisto¬chemical Quality Control (NordiQC, www.nordiqc.org), which was established in 2003 at the Institute of Pathology, Aalborg University Hospital, and currently serves more than 700 pathology laboratories from 85 countries.
|Allen M. Gown
Vice President Elect
|Dr. Gown received his M.D. from the Albert Einstein College of Medicine of Yeshiva University, Bronx, NY in 1975, and then completed his Pathology Residency as well as Pathology Fellowship training at the University of Washington, Seattle, the latter under the aegis of Dr. Earl Benditt. Dr. Gown rose through the ranks to full Professor of Pathology served as attending pathologist at the University of Washington Medical Center. He left the University of Washington to found PhenoPath, an internationally renowned reference laboratory, at the end of 1997, where he is currently Medical Director and Chief Pathologist. Dr. Gown is a pathologist-scientist recognized as one of the world’s leading experts in the diagnostic and research applications of immunohistochemistry (IHC). He has developed numerous clinically important monoclonal antibodies employed in pathology laboratories around the world (e.g., HMB-45, 34βE12, HHF35, OSCAR), and continues to be at the forefront of clinical investigative studies employing IHC and other modalities, publishing widely and presenting at national and international conferences. Dr. Gown is a member of the editorial boards of many of the major pathology journals. He is a Clinical Professor of Pathology at the University of British Columbia, Vancouver, BC, and an Affiliate Investigator in the Clinical Research Division of the Fred Hutchinson Cancer Research Center, Seattle, WA. Dr. Gown has contributed extensively to the expanding horizons of IHC with over 300 peer-reviewed publications.|
|Regan Fulton, MD PhD
|Dr. Fulton received his MD and PhD from the University of Minnesota, and completed his postgraduate training in Anatomic Pathology at Stanford University. Following residency, he completed two fellowships (Surgical Pathology and Immunodiagnosis) at Stanford University, and is board-certified in Anatomic Pathology.
Dr. Fulton worked at Kaiser Permanente Medical Center in San Francisco, CA for 12 years and served in the roles of Chief of Pathology, Assistant Chief of the Medical Center Quality Department and Medical Director of the Kaiser Regional IHC Laboratory and Consultation Service.
In addition to his extensive experience in diagnostic immunohistochemistry, Dr. Fulton served on the College of American Pathologists IHC Committee (2009 to 2014), as well as the CAP Workgroup for IHC Validation Guidelines. He is the founder and CEO of Array Science, LLC and holds a patent for a method and apparatus for making tissue and cell culture microarrays. This company received a National Cancer Institute-Small Business Innovations Research award to further develop this technology. He also serves on the scientific advisory boards for several companies in the biotechnology field.
Dr. Fulton joined PhenoPath Laboratories, Seattle, WA in September 2013 as attending pathologist and Director of Contract Research. In addition Dr. Fulton is actively involved in expert consultation and surgical pathology responsibilities, and the development and validation of new assays. Together with Dr. Allen Gown and Dr. Jason Hornick, Dr. Fulton serves on the faculty of a two-day course on Diagnostic Immunohistochemistry offered by the ASCP. He now serves as Secretary/Treasurer of the newly-formed International Society of Immunohistochemistry and Molecular Morphology.
|Richard W. Cartun, MS, PhD
Director, Histology & The Martin M. Berman, MD Immunopathology & Morphologic Proteomics Laboratory at Hartford Hospital
Society for Applied Immunohistochemistry
|Richard W. Cartun is the Director of Histology and the Martin M. Berman, MD Immunopathology/Morphologic Proteomics Laboratory at Hartford Hospital in Hartford, CT (USA). He also serves as the Director of Biospecimen Collection Programs and is the Assistant Director of Anatomic Pathology. Richard started working at Hartford Hospital as a Lab Tech in the Department of Pathology in July of 1978 after graduating from the University of Connecticut with a BS in Pathobiology. Over the next few years he earned an MS in Health Care Management from the Hartford Graduate Center/RPI and eventually obtained his PhD, also in Pathobiology, from UConn in 1990.
He performed the first immunoperoxidase “stain” at Hartford Hospital in 1979. He has been very active in the National Society for Histotechnology giving lectures/workshops and directing the NSH IHC Forum for the past 10 years. In addition, he has been involved in the Society for Applied Immunohistochemistry since 1993 and has spoken at many Society meetings over the years. He has given presentations at USCAP, ASCP, and international meetings on the subject of immunohistochemistry or what he now calls “Morphologic Proteomics”. His interests include the use of IHC in the detection of predictive markers in breast cancer, the identification of infectious agents, the use of IHC as a surrogate maker for gene alterations, and trouble-shooting IHC tests.
|Richard N. Eisen, MD
Society for Applied Immunohistochemistry
|Dr. Eisen currently is currently in practice with Phoenix Pathologists, Ltd., at Banner Thunderbird Medical Center in Glendale, AZ and holds a Clinical Faculty position at the University of Arizona, College of Medicine, Phoenix. Previously, he served as Attending Pathologist at Greenwich Hospital in the Yale New-Haven Health System from 1993-2015, as the Director of the Anatomic Pathologic Section and Immunohistochemistry Lab of the Clinical Laboratory. He received his MD degree from SUNY Downstate in 1984 and received his post-graduate training in Internal Medicine and Pathology at Yale University, the latter including a fellowship in Surgical Pathology under the directorship of Dr. Juan Rosai. He served on the full time Yale faculty until 1993, directing the Immunohistochemistry (IHC) Laboratory there for 2 years. Dr. Eisen has been involved with the Annual Retreat on Immunohistochemistry and Molecular Pathology since its inaugural meeting in 2007, as faculty and most recently assisting Dr. Hadi Yaziji in moderating and directing the course. Dr. Eisen has also served on the Board of Directors of The Society for Applied Immunohistochemistry since 1995 and as the Society’s President since 1997. He also served as Clinical Assistant and Associate Professor of Pathology at Yale University, teaching residents and medical students, from 1993-2015. Dr. Eisen has served as a member of the IHC Resource Committee of the College of American Pathologists (CAP) from 2004-2010 and is an active member of both CAP, ASCP and USCAP. He has also served as an advisor to the CAP Center Project on IHC Validation Guidelines, as a member of the CAP Center Project for Uniform Labeling Standards for Anatomic Pathology and as an Editorial Board member for the Journal of Applied Immunohistochemistry and Molecular Morphology.|
|C. Blake Gilks, MD FRCPC
|Dr. Blake Gilks is a Professor in the Dept of Pathology and Laboratory Medicine, at the University of British Columbia, in Vancouver Canada, and does clinical service work in the Division of Anatomic Pathology at Vancouver General Hospital, the site of the largest gynecological oncology program in the province of British Columbia, where he is director of the Division of Anatomical Pathology. He also currently serves as Interim Medical Director of Laboratories for the Vancouver Coastal Health region.
He graduated from Dalhousie University medical school in 1982 and did a residency in anatomical pathology at the University of British Columbia, followed by fellowships in gynecological pathology and molecular pathology at Massachusett's General Hospital and Fox Chase Cancer Center, respectively. Dr. Gilks leads a research program focused on gynecological cancers and is co-founder of the Genetic Pathology Evaluation Centre, a laboratory that uses tissue microarrays of human tumor samples for cancer research, and OvCaRe, a multidisciplinary team studying ovarian cancer. He is also co-founder and co-director of the Canadian Immunohistochemistry Quality Control program, which provides proficiency testing for Canadian diagnostic immunohistochemistry laboratories.
|Emina E. Torlakovic, MD PhD
Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada
Department of Laboratory Hematology, University Health Network, Toronto, Canada
|Dr. Emina Emilia Torlakovic earned her medical degree at the University of Zagreb Medical School and her PhD at the University of Oslo. She is Diplomate of the American Board of Pathology in Anatomic Pathology, Clinical Pathology, and Hematopatholgy. Dr. Torlakovic is a Professor of Pathology in the Department of Laboratory Medicine and Pathobiology, Faculty of Medicine, University of Toronto and practices as a consultant hematopathologist in the Department of Laboratory Hematology at the University Health Network, where she is also the Director of Biomarker Development and Quality Assurance. She was a founding member of Nordic Immunohistochemical Quality Control (NordiQC) and also co-founder of Canadian Immunohistochemistry Quality Control (CIQC). Dr. Torlakovic is also the Chair of the National Standards Committee for High Complexity Testing of the Canadian Association of Pathologists. Dr. Torlakovic has published over 90 peer-reviewed articles, authored a book on Bone Marrow Immunohistochemistry, and has lectured widely nationally and internationally on immunohistochemistry, quality assurance, and hematopathology.|
Senior biomedical scientist, Scheme Manager NordiQC, Institute of Pathology Aalborg University Hospital
|Søren Nielsen is senior biomedical scientist and project coordinator at Laboratory for immunohistochemistry/R&D, Institute of Pathology, Aalborg Hospital, Denmark, where he has worked within immunohistochemistry for more than 20 years. He is scheme manager of Nordic immunohistochemical Quality Control (NordiQC) initiated in 1998 and established as a professional organization in 2003. He functions as assessor and data analyst in the NordiQC general module, breast module and HER-2 ISH module. He is a regular lecturer and organizer of national and international immunohistochemical workshops, particularly in the field of protocol optimization and standardisation. He is author and co-author of more than 30 scientific papers and several book chapters based on immunohistochemical studies and is member of the editorial board of international journals.|
Clinical Professor of Pathology, Cumming School of Medicine, University of Calgary, Calgary AB
Professor of Pathology, University of Washington School of Medicine, Seattle WA
|After an undergraduate experience at Dartmouth College, Dr. Swanson received his medical training at Oregon Health Sciences University in Portland OR, during which time he completed a post-sophomore fellowship in pathology. He was introduced to immunohistochemical techniques at OHSU by Dr. Peter Stenzel, with whom he demonstrated the presence of neuron specific enolase in an example of urothelial small cell carcinoma (in 1983). He continued his pathology training at the University of Minnesota Hospital and Clinic, where he was given free reign to develop and refine mmunohistochemical applications in the anatomic pathology research laboratory directed by Dr Mark Wick. His interactions with a remarkable faculty in Minnesota at the time (including Drs. Juan Rosai, Louis Dehner, Richard Sibley, Glauco Frizzera, Dale Snover, Carlos Manivel and Dr Wick) gave him an appreciation for the wonders of academic surgical pathology as a specialty and the potential that immunohistochemistry held for the redefinition of an evolving field of inquiry. Though much of the glamour of the diagnostic lab has now shifted to molecular techniques, Dr. Swanson remains an ardent admirer of immunohistochemical methods and has focused on the delivery of appropriately optimized, calibrated and validated assays for clinical and investigative use. He regards immunohistochemistry as a place, perhaps even a state of mind, where diagnostic practice is unfettered by the largely artificial lines that divide today's subspecialty focus in surgical pathology (even though he might have to admit to a bit of a drift towards a clinical practice enriched in gastrointestinal diseases).|